A Phase I Placebo-controlled, Double-blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse's IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2018
At a glance
- Drugs IMCY-0098 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors ImCyse
- 30 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
- 19 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.